Clinical efficacy and safety of Tulosin (tamsulosin) in patients with benign prostatic hyperplasia

Sitdykova M.E.

The author presented results of the clinical study on efficacy and safety of alpha1-adrenoreceptor antagonist Tulosin (produced by «Egis») as a single agent therapy in patients with benign prostatic hyperplasia (BPH). The research team included 30 patients aged 50 to 82 years. Inclusion criteria – patients with BPH, expressiveness symptoms on a scale International Prostate Symptom Score (IPSS) more 9 points, the volume of residual urine not more than 100 ml. Treatment was conducted within 2 months, with compulsory monitoring of patient every month. Using phases of defining symptoms of the disease, blood analysis, definition of creatinine, ultrasound prostate visualisation with the definition of its volume and volume of residual urine, urofoumetry were also conducted. Specificity of side effects if they were available was estimated.

The study results indicate that in the course of therapy relieving infravesical obstruction occurs which confirmed by increase in urination rate and decrease in residual urine volume. Additionally benign prostatic hyperplasia symptoms abated as shown by the questionnaire IPSS and improving quality of life. Only 1 of 29 patients underwent surgery, transvesical adenomectomy was performed.

Therefore, Tulosin (tamsulosin) has a high efficacy and safety and may be recommended for treatment patients suffering from benign prostatic hyperplasia with significant irritative symptoms and moderate infravesical obstruction.